GlaxoSmithKline pulls Imus advertising prior to DJ’s dismissal

Share this article:
GlaxoSmithKline was among the advertisers to pull its ads from Don Imus’ talk show amid the controversy caused by remarks he made about the Rutgers University women’s basketball team. According to TNS Media Intelligence, GlaxoSmithKline was the No. 5 advertiser on the MSNBC telecast of Imus’ show during 2006, spending $277,900. “The bottom line is that we have suspended our advertising with MSNBC until we can determine that we can have a level of confidence that our media standards are being adhered to,” GlaxoSmithKline spokeswoman Nancy Pekarek told MM&M. Pekarek said Glaxo did not buy any advertising space on Imus’ radio program. “What we did do was buy advertising on MSNBC. That put us on a rotation and that’s how the ads appeared on MSNBC in that time slot,” she said. Glaxo was among a number of companies to remove their advertising from Imus’ show prior to the shock jock’s firing over racially insensitive remarks last week.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...